News
Nov 23, 2024
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a significant boost in the market against…
Nov 22, 2024
Transthyretin amyloid cardiomyopathy (ATTR-CM) patients treated with the amyloidosis drug acoramidis are associated with significantly lower mortality and…
Nov 22, 2024
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of…
Nov 18, 2024
- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk…
Nov 12, 2024
Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-…
Nov 11, 2024
Background: Acoramidis is a novel, potent, investigational, transthyretin (TTR) stabilizer under development for the treatment of TTR amyloidosis that results in…
Nov 10, 2024
The PAN Foundation helps people living with life-threatening, chronic, and rare diseases with financial help for out-of-pocket treatment costs. Join to learn about…
Nov 05, 2024
DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics…
Nov 03, 2024
The year is flying by and you are invited to a Christmas morning tea in December.The venue, time and place is, as always, set out on the right. I am really looking…